Thu, Nov 27, 2014, 5:17 PM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

NuPathe Inc. Message Board

  • g_dargusch g_dargusch Apr 25, 2013 8:02 AM Flag

    Nupathe announces allowance of U.S. Patent Application for NP201

    looks like we R continueing our path forward,,,jmo,g

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • CONSHOHOCKEN, PA -- (Marketwired) -- 04/25/13 -- NuPathe Inc.(PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 12/074,101 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to a biodegradable polymer implant capable of delivering a dopamine modulating compound, such as ropinirole, with little or no initial burst and maintaining an effective plasma level for a specified period of time. Given this action, NuPathe(PATH) expects the patent to issue within the next few months. Once issued, it will provide patent protection into July 2028 for NP201, NuPathe's(PATH) long-term biodegradable ropinirole implant for the treatment of Parkinson's disease. NuPathe(PATH) has additional licensed patent applications pending in the U.S. and other territories for NP201.

      "We are pleased with the USPTO's allowance and believe a strong patent portfolio for NP201 is an important valuable component of the value proposition as we seek development partners for this program," said Armando Anido, chief executive officer of NuPathe(PATH). "While obtaining this patent is important, we remain focused on securing commercial partners and preparing for the launch of ZECUITY."

4.250.00(0.00%)Feb 21 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.